Advertisement

Topics

Gene therapy developer Paragon reportedly to be bought by Catalent

06:31 EDT 16 Apr 2019 | SmartBrief

Catalent, a contract drugmaker, reportedly has agreed to pay $1.2 billion for Paragon Bioservices, a privately held gene ther -More

Original Article: Gene therapy developer Paragon reportedly to be bought by Catalent

NEXT ARTICLE

More From BioPortfolio on "Gene therapy developer Paragon reportedly to be bought by Catalent"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...